KALA BIO, Inc. — Director's Dealing 2020

Oct 29, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2020-06-05

Reporting Person: Bazemore Todd (Chief Operating Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-26	Common Stock	A	81000	—	Acquired	110000	Direct
2020-06-05	Common Stock	P	2	$13.39	Acquired	2	Indirect
2020-10-22	Common Stock	P	40	$7.60	Acquired	42	Indirect

Footnotes

F1: On June 25, 2020, the reporting person was granted performance-based restricted stock unit ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with the Issuer, the RSUs will vest as to 50% of the shares underlying the RSUs on October 26, 2021, the first anniversary of the achievement of the performance condition, and as to the remaining 50% of the shares underlying the RSUs on October 26, 2022, the second anniversary of the achievement of the performance condition.

F2: Includes 100,000 unvested RSUs.

F3: These transactions are being reported late because these shares were acquired by the reporting person's adult son without the reporting person's knowledge.

F4: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.